PA
VRNA

Parallel Advisors’s Verona Pharma VRNA Stock Holding History

Parallel Advisors’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$11K – 3308
2021
Q3 		$11K Hold
2,000
– – ﹤0.01% 2038
2021
Q2 		$13K Buy
+2,000
New +$13.9K ﹤0.01% 1913

Other funds holding VRNA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Parallel Advisors's VRNA Position: Q4 2021 in Review

Parallel Advisors sold out of Verona Pharma (VRNA) in Q4 2021, closing a stake of 2,000 shares — an estimated $11K sold.

Parallel Advisors first reported a position in VRNA in Q2 2021 and held it in 2 quarters. The position peaked at $13K in Q2 2021. 42 funds tracked by Wall St. Rank hold VRNA as of Q4 2021.

  • Parallel Advisors reported no remaining Verona Pharma position as of Q4 2021 after selling out during the quarter.
  • Parallel Advisors sold 2,000 Verona Pharma shares in Q4 2021, an estimated $11K.
  • Parallel Advisors first reported a position in Verona Pharma in Q2 2021 and held it in 2 quarters.
  • Parallel Advisors's Verona Pharma position peaked at $13K in Q2 2021.
  • 42 funds tracked by Wall St. Rank held Verona Pharma as of Q4 2021.

Based on Parallel Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.